Augurex Life Sciences Corp.

Market position

The company positions itself as a leader in biomarker-driven clinical diagnostics for autoimmune conditions and a pioneer of 14-3-3η-based diagnostics, describing SPINEstat as a potential first-in-class diagnostic for ankylosing spondylitis. Context cited in 2017 noted the Arthritis Alliance of Canada's estimate of $5.7 billion in annual direct and indirect RA costs, with 1 in every 136 workers affected, and an approximately 30% remission rate with the most advanced available therapies.

Augurex's tests are built on the 14-3-3η protein, a biomarker it pioneered, enabling earlier detection than assessment based on later-stage disease indicators and prognostic information on joint damage risk. SPINEstat addresses axial spondyloarthritis, a condition often misdiagnosed as low back pain, as what the company describes as a first-in-class diagnostic.

Technology

The core technology is detection of the 14-3-3η protein in blood. 14-3-3η is described as a very early contributor to disease that correlates with joint damage prognosis, making it useful for early RA diagnosis, prediction of RA onset in patients with joint pain, and monitoring joint damage risk. A broader portfolio of 14-3-3η-centric biomarkers has been shown to have applications across multiple autoimmune diseases with joint involvement, and a preclinical therapeutic program emerged from the same work.

Go-to-market

The company reaches patients through laboratory partnerships and regulatory clearances in multiple jurisdictions: JOINTstat is Health Canada approved and launched by LifeLabs in Canada, CE marked for Europe and TGA approved for Australia, while U.S. clinical laboratories purchase analyte specific reagents to build their own 14-3-3η-based tests. Since inception the company has used government programs, angel networks and academic scientific opinion leaders alongside its LifeLabs relationship.

Rheumatologists and other physicians, clinical laboratories, and patients with or at risk of autoimmune diseases affecting the joints, including rheumatoid arthritis and axial spondyloarthritis.

Geography

Headquartered at 220 - 887 Great Northern Way, Vancouver, British Columbia, V5T 4T5, Canada. Products are cleared or available in Canada, the United States, Europe (CE mark) and Australia (TGA).

History

The company originated from a 2006 university invention and commenced operations in 2008 under co-founder Norma Biln. JOINTstat entered clinical use in the United States in late 2013, received Health Canada approval and was launched in Canada by laboratory services provider LifeLabs; by early 2017 it had been studied in more than 4,000 patients and had received CE marking and TGA approval for clinical use in Europe and Australia. In February 2017, Genome BC invested in the company through its Industry Innovation (I²) Program, with proceeds intended to support the launch of additional blood tests from the pipeline and advancement of the therapeutic program. In August 2024, Neil Klompas was appointed President and CEO, succeeding Biln, who moved into an interim role as global head of product research and development while remaining Chair of the Board.

Risks & controversies

The company notes that RA patients still experience roughly a 30% non-remission rate even with the most advanced therapies, underscoring clinical need but also the limits of current management. Commentary from the company in 2017 highlighted difficulty accessing government funding at later commercialization stages as a financing risk for companies at its stage.